van den Berg MP, van Gelder IC, van Veldhuisen DJ: Impact of atrial fibrillation on mortality in patients with chronic heart failure. Eur J Heart Fail. 2002, 4 (5): 571-575. 10.1016/S1388-9842(02)00094-6.
Article
PubMed
Google Scholar
Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB: Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998, 158 (3): 229-10.1001/archinte.158.3.229.
Article
PubMed
CAS
Google Scholar
Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998, 82 (7): 2N-9N. 10.1016/S0002-9149(98)00583-9.
Article
PubMed
CAS
Google Scholar
Ruigómez A, Johansson S, Wallander MA, Rodríguez LG: Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation. BMC Cardiovasc Disord. 2002, 2 (1): 5-10.1186/1471-2261-2-5.
Article
PubMed
PubMed Central
Google Scholar
Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN: The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol. 2007, 50 (1): 35-10.1097/FJC.0b013e3180547553.
Article
PubMed
CAS
Google Scholar
Fedida D, Orth PMR, Hesketh JC, EZRIN AM: The role of late INa and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol. 2006, 17: S71-S78. 10.1111/j.1540-8167.2006.00386.x.
Article
PubMed
Google Scholar
Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH: Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010, 106 (9): 1277-1283. 10.1016/j.amjcard.2010.06.054.
Article
PubMed
CAS
Google Scholar
Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B: Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008, 117 (12): 1518-1525. 10.1161/CIRCULATIONAHA.107.723866.
Article
PubMed
CAS
Google Scholar
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis J, Clarke M, Devereaux P, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009, 62 (10): e1-e34. 10.1016/j.jclinepi.2009.06.006.
Article
PubMed
Google Scholar
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17 (1): 1-12. 10.1016/0197-2456(95)00134-4.
Article
PubMed
CAS
Google Scholar
Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G: A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011, 57 (3): 313-321. 10.1016/j.jacc.2010.07.046.
Article
PubMed
Google Scholar
Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S: A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004, 44 (12): 2355-2361. 10.1016/j.jacc.2004.09.021.
Article
PubMed
CAS
Google Scholar
Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA: Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department. Acad Emerg Med. 2010, 17 (11): 1175-1182. 10.1111/j.1553-2712.2010.00915.x.
Article
PubMed
Google Scholar
Savelieva I, Camm J: Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace. 2008, 10 (6): 647-665. 10.1093/europace/eun130.
Article
PubMed
Google Scholar
Kalus JS: Pharmacologic management of atrial fibrillation: established and emerging options. J Manag Care Pharm. 2009, 15 (6): S10-18.
PubMed
Google Scholar
Kowey P, Roy D, Pratt C, Schwartz P, Dorian P, Mitchell L, Toft E: Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery. Circulation. 2007, 116: 7-
Google Scholar
Cheng JW: Vernakalant in the management of atrial fibrillation. Ann Pharmacother. 2008, 42 (4): 533-542. 10.1345/aph.1K542.
Article
PubMed
CAS
Google Scholar